Baylor Genetics

Belkins
Baylor Genetics is a joint venture of Miraca Holdings, Inc. and Baylor College of Medicine, including the #1 NIH-funded Department of Molecular and Human Genetics. A pioneer of precision medicine for nearly 40 years, Baylor Genetics now offers a full spectrum of clinically relevant genetic testing, access to world-renowned experts, and the confidence to provide patients with the best care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

US DRUG TEST CENTERS NOW OFFERING NATIONWIDE COVID-19 ANTIBODY TESTING

US Drug Test | July 21, 2020

news image

US Drug Test Centers, one of the largest testing companies in the United States, announced they are now offering COVID-19 Antibody Testing with FDA Emergency Use Authorization at 1,800+ locations nationwide. No prescription is necessary. To book an appointment, visit www.usdrugtestcenters.com, select a location, order a test and an order from a local doctor will be sent to you in 6-12 hours. The test includes a simple blood draw, and results are received usually within 24-48 hours.Antibody...

Read More

CELL AND GENE THERAPY

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

BrainStorm Cell Therapeutics | October 26, 2020

news image

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

news image

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

CELL AND GENE THERAPY

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

news image

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More

US Drug Test | July 21, 2020

news image

US DRUG TEST CENTERS NOW OFFERING NATIONWIDE COVID-19 ANTIBODY TESTING

US Drug Test Centers, one of the largest testing companies in the United States, announced they are now offering COVID-19 Antibody Testing with FDA Emergency Use Authorization at 1,800+ locations nationwide. No prescription is necessary. To book an appointment, visit www.usdrugtestcenters.com, select a location, order a test and an order from a local doctor will be sent to you in 6-12 hours. The test includes a simple blood draw, and results are received usually within 24-48 hours.Antibody...

Read More

CELL AND GENE THERAPY

BrainStorm Cell Therapeutics | October 26, 2020

news image

RAPID RESHORE & DEVELOPMENT AND BRAINSTORM CELL THERAPEUTICS ANNOUNCE AGREEMENT TO ADVANCE CONSTRUCTION OF BRAINSTORM'S U.S. MANUFACTURING FACILIT

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegener...

Read More

Biomeme | August 20, 2020

news image

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

CELL AND GENE THERAPY

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

news image

MRNA VICTORIA AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO GROW THE BIOECONOMY & INTERNATIONAL BIOSECURITY CAPABILITIES

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first ...

Read More